Methods and reagents for extracorporeal immunomodulatory therapy
OwnerSamuel Ackerman, Clark M. Edson +2inventors
InventorsSamuel Ackerman, Clark M. Edson, Loren Fast, Andrei Purmal
Life of this patent
Estimating the term…
Abstract
The invention features methods for altering the immunomodulatory activity of compositions containing peripheral blood mononuclear cells. The methods include the steps of contacting PBMCs with an amount of an aziridino-containing compound effective to react with and modify the PBMC nucleic acid.
Claims35
A method for treating a patient having an immune dysfunction, said method comprising the steps of:
- (a) treating peripheral blood mononuclear cells with an effective amount of an aziridino-containing compound;
- and
- (b) administering said peripheral blood mononuclear cells to said patient.
A method for treating a patient having an immune dysfunction, said method comprising the steps of:
- (a) extracorporeally treating peripheral blood mononuclear cells from said patient with an effective amount of an aziridino-containing compound;
- (b) separately said peripheral blood mononuclear cells from said aziridino-containing compound;
- and
- (c) administering said peripheral blood mononuclear cells to said patient.
A method for preventing graft-versus-host (GVH) disease in a patient, the method comprising the steps of:
- (a) extracorporeally treating a blood composition with an effective amount of an aziridino-containing compound;
- and
- (b) administering said treated blood cell population to said patient,
- thereby preventing GVH disease in said patient.
A method for preventing graft-versus-host (GVH) disease in a patient, the method comprising the steps of:
- (a) treating a heterologous blood composition with an effective amount of an ethylene oligomer compound;
- (b) removing said ethylene oligomer from said heterologous treated blood composition;
- and
- (c) administering said treated blood cell population to said patient,
- thereby preventing GVH disease in said patient.
A method for treating graft-versus-host (GVH) disease in a patient, the method comprising the steps of:
- (a) treating a heterologous blood composition with an effective amount of an aziridino-containing compound;
- and
- (b) administering said treated blood cell population to said patient,
- thereby treating GVH disease in said patient.
A method for preventing graft-versus-host (GVH) disease in a patient, the method comprising the steps of:
- (a) treating a heterologous blood composition with an effective amount of an ethylene oligomer compound;
- (b) removing said ethylene oligomer from said heterologous treated blood composition;
- and
- (c) administering said treated blood cell population to said patient,
- thereby preventing GVH disease in said patient.
A method for preventing an alloantibody response in a patient, the method comprising the steps of:
- (a) treating a heterologous blood composition with an effective amount of an aziridino-containing compound;
- and
- (b) administering said treated blood cell population to said patient,
- thereby preventing said alloantibody response in said patient.
A method for functionally inactivating a leukocyte in a patient, the method comprising the steps of:
- (a) treating a heterologous blood composition comprising a leukocyte with an effective amount of an aziridino-containing compound;
- and
- (b) administering said treated blood cell population to said patient,
- thereby inactivating said leukocyte in said patient.
A blood composition produced by treating a composition comprising peripheral blood mononuclear cells with a non-viricidal amount of an aziridino-containing compound. wherein said aziridino-containing compound is present in an amount sufficient to inhibit proliferation of said peripheral blood mononuclear cells.
Dependencies are inferred from the claim text.